期刊文献+
共找到23篇文章
< 1 2 >
每页显示 20 50 100
芪精抗艾胶囊治疗艾滋病 被引量:4
1
作者 南红梅 南征 +4 位作者 臧立权 王雪冰 金惠英 李娜 王学杰 《吉林中医药》 2014年第3期265-268,共4页
目的观察芪精抗艾胶囊治疗艾滋病的疗效。方法治疗组50例,口服芪精抗艾胶囊、拉米夫定、齐多夫定、奈韦拉平联合治疗;对照组50例,用拉米夫定、齐多夫定、奈韦拉平联合治疗。4周为1个疗程。结果6个疗程后,治疗组总有效率为90%,对照组为70... 目的观察芪精抗艾胶囊治疗艾滋病的疗效。方法治疗组50例,口服芪精抗艾胶囊、拉米夫定、齐多夫定、奈韦拉平联合治疗;对照组50例,用拉米夫定、齐多夫定、奈韦拉平联合治疗。4周为1个疗程。结果6个疗程后,治疗组总有效率为90%,对照组为70%。治疗组治疗后CD4+T淋巴细胞水平均明显上升,而对照组治疗后CD4+T淋巴细胞水平无明显改善,2组治疗后CD4+T淋巴细胞比较,差异有统计学意义(P<0.05)。2组中医症状均有改善,治疗组优于对照组。结论芪精抗艾胶囊能明显升高艾滋病患者的CD4+T淋巴细胞的水平,下降病毒载量,改善临床症状。 展开更多
关键词 滋病 芪精抗艾胶囊 CD4^+T淋巴细胞
下载PDF
壮药“抗艾1号”干预HIV感染治疗疗效对比观察 被引量:3
2
作者 钟鸣 吴锋耀 +5 位作者 宋兴武 欧健 梁飞立 余胜民 滕红丽 蓝日春 《中国民族医药杂志》 2015年第8期3-5,共3页
目的:通过壮药制剂"抗艾1号"介入HIV感染ART治疗疗效观察,探求壮医药治疗HIV感染的可能性,为壮医药治疗HIV感染寻找有效方剂。方法:选取HIV确诊阳性感染拟进入ART治疗的患者107人,随机分成对照组51例和观察组56例,对照组按方... 目的:通过壮药制剂"抗艾1号"介入HIV感染ART治疗疗效观察,探求壮医药治疗HIV感染的可能性,为壮医药治疗HIV感染寻找有效方剂。方法:选取HIV确诊阳性感染拟进入ART治疗的患者107人,随机分成对照组51例和观察组56例,对照组按方案给予常规ART抗病毒治疗,观察组在常规ART方案基础上,在治疗开始即加服壮药"抗艾1号"治疗,记录治疗前、治疗3个月后的症状体征积分、血常规、肝肾功能及CD4+T淋巴细胞等数据,对比其组内及组间治疗前后的变化。结果:壮药制剂"抗艾1号"介入HIV抗病毒治疗3个月后,在改善临床症状和免疫功能特别提升CD4+T淋巴细胞效果更明显。结论:壮药制剂"抗艾1号"有改善艾滋病患者症状,提高免疫力和生存质量的作用。 展开更多
关键词 壮医药 HIV感染 疗效 抗艾1号
下载PDF
雅培公司与巴西政府就抗艾药物蛋白酶抑制剂Kaletra达成协议
3
《医药化工》 2005年第8期45-45,共1页
近期,雅培公司与巴西政府就蛋白酶抑制剂Kaletra(洛匹那韦/利托那韦)达成了协议。雅培公司同意在未来6年大大降低Kaletra的价格,向巴西提供两年后将在全球推出的Kaletra新配方,并于2009年开始向巴西制药厂转让该药品的生产技术,... 近期,雅培公司与巴西政府就蛋白酶抑制剂Kaletra(洛匹那韦/利托那韦)达成了协议。雅培公司同意在未来6年大大降低Kaletra的价格,向巴西提供两年后将在全球推出的Kaletra新配方,并于2009年开始向巴西制药厂转让该药品的生产技术,并于2012年投产。此外,雅培公司还保证,无论患者人数增加多少,今后6年内继续免费为患艾滋病的巴西儿童提供Kaletra。巴西政府也决定继续保护雅培公司的专利。 展开更多
关键词 雅培公司 巴西 抗艾药物蛋白酶抑制剂 市场价格 配方 市场需求 生产技术
下载PDF
抗艾牛痘可能在华临床研究
4
《医学研究通讯》 2004年第10期28-28,共1页
2004年全球华人生物科学家大会上,艾滋病病毒生物学药物的研究将成为学术交流的“重头戏”。美国洛克菲勒大学的科学家构建了两种抗艾滋病DNA疫苗,并把其HIV-1基因嵌合入了一种安全性极高的牛痘株,命名为改进的安卡拉牛痘。据专家透露,... 2004年全球华人生物科学家大会上,艾滋病病毒生物学药物的研究将成为学术交流的“重头戏”。美国洛克菲勒大学的科学家构建了两种抗艾滋病DNA疫苗,并把其HIV-1基因嵌合入了一种安全性极高的牛痘株,命名为改进的安卡拉牛痘。据专家透露,对这种牛痘的临床研究有可能在中国进行。 展开更多
关键词 抗艾牛痘 临床研究 滋病病毒生物学药物 安卡拉牛痘
下载PDF
网络药理学视角下蕲艾抗炎潜能及其作用机制研究
5
作者 冯智龙 孔明霞 《黄冈职业技术学院学报》 2024年第2期82-85,共4页
通过网络药理学方法研究蕲艾的抗炎潜能及作用机制。运用网络药理学方法在SymMap、DisGenet和GeneCards数据库获取蕲艾相关成分以及抗炎靶点数据,并通过韦恩图和蛋白质相互作用网络分析了共同靶点。从29个核心靶点中识别出关键蛋白质,... 通过网络药理学方法研究蕲艾的抗炎潜能及作用机制。运用网络药理学方法在SymMap、DisGenet和GeneCards数据库获取蕲艾相关成分以及抗炎靶点数据,并通过韦恩图和蛋白质相互作用网络分析了共同靶点。从29个核心靶点中识别出关键蛋白质,并展示这些蛋白质在抗炎症通路中的重要性,进一步揭示了CXCL2、PTGS2、IL6、CXCL8、CXCL1等基因在整个网络中的关联和重要性。研究结果表明,蕲艾通过调节这些基因有参与抗炎的作用,为其作为抗炎药物的科学应用提供了理论依据。 展开更多
关键词 网络药理学 作用机制
下载PDF
防艾抗艾的个体道德思考
6
作者 王友良 康萃 《休闲》 2021年第5期0065-0065,共1页
自 1988 年 12 月 1 日诊断出第一例艾滋病感染者起,此后将每年的 12 月 1 日被定为世界艾滋病日,从发现第一例艾滋病感染者到现在在短短的 30 余年间,艾滋病已席卷全球,至2019 年全球已有 3800 多万人感染艾滋病毒,在我国,艾滋病已成... 自 1988 年 12 月 1 日诊断出第一例艾滋病感染者起,此后将每年的 12 月 1 日被定为世界艾滋病日,从发现第一例艾滋病感染者到现在在短短的 30 余年间,艾滋病已席卷全球,至2019 年全球已有 3800 多万人感染艾滋病毒,在我国,艾滋病已成为致死人数最多的传染病。因此加快落实艾滋病预防,携手抗艾成为全民的共同的健康责任。 展开更多
关键词 抗艾
下载PDF
抗HIV/AIDS药物的市场现状和发展趋势分析 被引量:3
7
作者 沈燕玲 王毅红 吴卫星 《中国医药技术经济与管理》 2008年第7期29-38,共10页
本文根据大量详实的数据,侧重于不同种类药物的销售额和市场占有率,对抗HIV/ AIDS药物的市场和发展趋势进行较为全面的分析。并通过对进入后期临床研究的新药候选者的分析,展望了未来即将上市的抗HIV/AIDS新药。文章体现了新药开发和市... 本文根据大量详实的数据,侧重于不同种类药物的销售额和市场占有率,对抗HIV/ AIDS药物的市场和发展趋势进行较为全面的分析。并通过对进入后期临床研究的新药候选者的分析,展望了未来即将上市的抗HIV/AIDS新药。文章体现了新药开发和市场相互作用的思想,对我国新药研究和企业发展战略提供了有价值的参考。 展开更多
关键词 抗艾 市场现状 发展趋势
下载PDF
几种植物源抗菌粘胶纤维性能的对比研究 被引量:6
8
作者 刘卫 赵艳艳 于湖生 《山东纺织科技》 2016年第1期19-21,共3页
文章将茶叶抗菌粘胶纤维、艾草抗菌粘胶纤维、金樱子抗菌粘胶纤维、千年健粘胶纤维与普通粘胶纤维相对比,测试了它们的基本性能和抗菌性能。结果表明虽然这几种植物源抗菌纤维的基本性能与普通粘胶纤维有所差异,但仍能满足纺织生产和服... 文章将茶叶抗菌粘胶纤维、艾草抗菌粘胶纤维、金樱子抗菌粘胶纤维、千年健粘胶纤维与普通粘胶纤维相对比,测试了它们的基本性能和抗菌性能。结果表明虽然这几种植物源抗菌纤维的基本性能与普通粘胶纤维有所差异,但仍能满足纺织生产和服用性能的要求,而且这些纤维具有很好的抗菌性能。 展开更多
关键词 茶叶菌粘胶纤维 菌粘胶纤维 金樱子菌粘胶纤维 千年健菌粘胶纤维 基本性能 菌性能
下载PDF
Aptivus
9
作者 许关煜(编译) 《中国处方药》 2007年第10期15-15,共1页
勃林格殷格翰公司的抗艾新药Aptivus(tipranavir)已经通过了FDA的最终上市批准。
关键词 抗艾新药 Aptivus 勃林格殷格翰公司 蛋白酶抑制剂
下载PDF
A Few Specialized Issues That Should Be Focused on Anti-HIV Drug Evaluation In Vitro
10
作者 Dao-min ZHUANG Jing-yun LI 《Virologica Sinica》 SCIE CAS CSCD 2010年第4期301-306,共6页
Since the introduction of antiretroviral therapy (ART), the lifespan and quality of life of patients infected with HIV have been significantly improved. But treatment efficacy was compromised eventually by the develop... Since the introduction of antiretroviral therapy (ART), the lifespan and quality of life of patients infected with HIV have been significantly improved. But treatment efficacy was compromised eventually by the development of resistance to antiretroviral drugs, and more new anti-HIV drugs with lower toxicity and higher activity were needed. Based on the experience and lessons learned from the treatment in the developed countries, US FDA suggested that more pharmacodynamical researches should be considered ahead of the clinical trials. To facilitate the anti-HIV drug research and development, we reviewed a few specialized issues that should be focused on drug evaluations in vitro, including: 1) Mechanism of action studies, demonstrating the candidate drug's efficacy to specifically inhibit viral replication or a virus-specific function and confirm the drug target. 2) Drug resistance studies, selecting the drug-resistant variants in vitro and determining the activities inhibiting HIV isolates resistant to approved antiretroviral drugs of the same class. 3) Antiviral activity in vitro in the presence of serum proteins, ascertaining whether an investigational product is significantly bound by serum proteins. 4) Combination activity analysis, evaluating in vitro antiviral activity of an investigational product in two-drug combinations with other drugs approved. 展开更多
关键词 Human immunodeficiency virus Drug evaluation Drug resistance
下载PDF
Towards a cure for HIV: the identification and characterization of HIV reservoirs in optimally treated people
11
作者 Adewunmi Onafuwa-Nugal Lucy A McNamara Kathleen L Collins 《Cell Research》 SCIE CAS CSCD 2010年第11期1185-1187,共3页
Currently available anti-HIV-1 drugs suppress viral replication and maintain viral levels below the detection threshold of most assays but do not eliminate cellular reservoirs. As a result, very low levels of circulat... Currently available anti-HIV-1 drugs suppress viral replication and maintain viral levels below the detection threshold of most assays but do not eliminate cellular reservoirs. As a result, very low levels of circulating virus can be detected in most people despite long-term treatment with potent anti-HIV drug combinations. Not surprisingly, viral levels rebound with discontinuation of treatment. New evidence indicates that there is a viral reservoir in bone marrow progenitor cells. 展开更多
关键词 HIV LATENCY bone marrow stem cells CD34
下载PDF
Protective Actions of Blumea Flavanones on Primary Cultured Hepatocytes and Liver Subcellular Organelle against Lipid Peroxidation
12
作者 赵金华 许实波 +2 位作者 王正濂 林永成 陈荣礼 《Journal of Chinese Pharmaceutical Sciences》 CAS 1998年第3期40-44,共5页
To search for the protective actions of blumea flavanones (BFs) on hepatocytes and hepatic subcellular organelle against lipid peroxidation, monkey′s hepatocytes were isolated and cultured with or without blumea flav... To search for the protective actions of blumea flavanones (BFs) on hepatocytes and hepatic subcellular organelle against lipid peroxidation, monkey′s hepatocytes were isolated and cultured with or without blumea flavanones, then damaged by FeSO 4 cysteine or CCl 4. The lipid peroxidation (malondialdehyde production) and alteration in hepatocyte membrane (leakage of GPT) were estimated. Hepatic subcellular organelles were also isolated and incubated with or without blumea flavanones, then injured by FeSO 4 ascorbate. The generation of malondialdehyde(MDA) was measured. It was found that BFs 10 and 100 μmol·L 1 inhibited the MDA generation and GPT (glutamic pyruvic transaminase) leakage out of hepatocytes that were induced by CCl 4 or FeSO 4 cysteine. BFs could prevent lipid peroxidation initiated by FeSO 4 ascorbate in subcellular organelle suspension. Among BFs, BF 2 possessed the strongest activity. Conclusion: Blumea flavanones possess antioxidation activities that protect monkey′s hepatocytes and hepatic subcellular organelle against injuries induced by FeSO4 or CCl 4. 展开更多
关键词 Blumea flavanones Antioxidants Macaca mulatta HEPATOCYTE Subcellular organelle
全文增补中
“Unconventional”Neutralizing Activity of Antibodies Against HIV 被引量:1
13
作者 Michael WEN Paul ZHOU 《Virologica Sinica》 SCIE CAS CSCD 2007年第6期462-470,共9页
Neutralizing antibodies are recognized to be one of the essential elements of the adaptive immune response that must be induced by an effective vaccine against HIV. However, only a limited number of antibodies have be... Neutralizing antibodies are recognized to be one of the essential elements of the adaptive immune response that must be induced by an effective vaccine against HIV. However, only a limited number of antibodies have been identified to neutralize a broad range of primary isolates of HIV-1 and attempts to induce such antibodies by inununization were unsuccessful. The difficulties to generate such antibodies are mainly due to intrinsic properties of HIV-1 envelope spikes, such as high sequence diversity, heavy glycosylation, and inducible and transient nature of certain epitopes. In vitro neutralizing antibodies are identified using "conventional" neutralization assay which uses phytohemagglutinin (PHA)-stimulated human PBMCs as target cells. Thus, in essence the assay evaluates HIV-1 replication in CD4^+T cells. Recently, several laboratories including us demonstrated that some monoclonal antibodies and HIV-1-specific polyclonal IgG purified from patient sera, although they do not have neutralizing activity when tested by the "conventional" neutralization assay, do exhibit potent and broad neutralizing activity in "unconventional" ways. The neutralizing activity of these antibodies and IgG fractions is acquired through post-translational modifications, through opsonization of virus particles into macrophages and inunature dendritic cells (iDCs), or through expression of antibodies on the surface of HIV-1-susceptible cells. This review will focus on recent findings of this area and point out their potential applications in the development of preventive strategies against HIV. 展开更多
关键词 ANTIBODY Neutralizing activity Human immunodeficiency virus (HIV)
下载PDF
A Study in vitro on the Synergetic Cytocidal Effect ofAscorbic Acid and Mitomycin C against the Ehrlich As-cites Tumor Cells in Culture
14
作者 闵熙 李泮海 庞贻慧 《Journal of Chinese Pharmaceutical Sciences》 CAS 1995年第3期118-124,共7页
The synergetic cytocidal effect of ascorbic acid and mitomycin C on Ehrlich as-cites tumor cells in culture was studied. The chain scission of DNA by Cu(Ⅱ)mitomycin C/ascorbic acid system,and the chemical kinetics of... The synergetic cytocidal effect of ascorbic acid and mitomycin C on Ehrlich as-cites tumor cells in culture was studied. The chain scission of DNA by Cu(Ⅱ)mitomycin C/ascorbic acid system,and the chemical kinetics of the Cu(Ⅱ) catalyzed aerobic oxidation of ascorbic acid in the presence of mitomycin C were also discussed. Experimental results showed that ascorbic acid and mitomycin C were synergetic in destroying Ehrlich ascites tumor cells.The effect is related to the breaking action of the Cu(Ⅱ)mitomycin C/ascorbic acid system on the DNA chain, and to the quantity of the system produced ·OH, and the speed of production which are both directly proportional to the concentration of ascorbic aci.These results imply that the ·OH produced in the aerobic oxidation of ascorbic acid,and·OH induced scission of DNA chain, are important factors to he synergetic cytocidal effect of ascorbic acid and mitomycin C on Ehrlich ascites tumor cells. 展开更多
关键词 Ascorbic acid Mitomycin C Ehrlich ascites tumor cells Chain scission of
下载PDF
Current Status of Targets and Assays for Anti-HIV Drug Screening 被引量:1
15
作者 Ren-rong TIAN Qing-jiao LIAO Xu-lin CHEN 《Virologica Sinica》 SCIE CAS CSCD 2007年第6期476-485,共10页
HIV/AIDS is one of the most serious public health challenges globally. Despite the great efforts that are being devoted to prevent,treat and to better understand the disease,it is one of the main causes of morbidity a... HIV/AIDS is one of the most serious public health challenges globally. Despite the great efforts that are being devoted to prevent,treat and to better understand the disease,it is one of the main causes of morbidity and mortality worldwide. Currently,there are 30 drugs or combinations of drugs approved by FDA. Because of the side-effects,price and drug resistance,it is essential to discover new targets,to develop new technology and to find new anti-HIV drugs. This review summarizes the major targets and assays currently used in anti-HIV drug screening. 展开更多
关键词 ANTI-HIV TARGETS Assays Drug screening
下载PDF
Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexuals 被引量:1
16
作者 Pascal Gervaz Alexandra Calmy +2 位作者 Ymer Durmishi Abdelkarim S Allal Philippe Morel 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第25期2987-2991,共5页
Squamous cell carcinoma of the anus (SCCA) is a com- mon cancer in the human immunodeficiency virus (HIV)- infected population, and its incidence continues to in- crease in male homosexuals. Combined chemoradiatio... Squamous cell carcinoma of the anus (SCCA) is a com- mon cancer in the human immunodeficiency virus (HIV)- infected population, and its incidence continues to in- crease in male homosexuals. Combined chemoradiation with mitomycin C and 5-fiuorouracil was poorly tolerated by severely immunocompromised patients in the early 1990s. In the era of highly active antiretroviral therapy (HAART), however, recent data indicate that: (1) most HIV patients with anal cancer can tolerate standard chemotherapy regimens; and (2) this approach is associ- ated with survival rates similar to those of HIV-negative patients. However, HIV-positive patients with SCCA are much younger, more likely to develop local tumor recur- rence, and ultimately die from anal cancer than immune competent patients. Taken together, these findings suggest that anal cancer is an often fatal neoplasia in mid- dle-aged HIV-positive male homosexuals. In this popula- tion, SCCA is an opportunistic disease resulting in patients with suboptimal immune function from persistent infection and prolonged exposition to oncogenic human papillomaviruses (HPVs). Large-scale cancer-prevention strategies (routine anuscopy and anal papanicolaou test- ing) should be implemented in this population. In addi- tion, definitive eradication of oncogenic HPVs within the anogenital mucosa of high-risk individuals might require a proactive approach with repeated vaccination. 展开更多
关键词 Anal cancer CHEMORADIATION Highly activeantiretroviral therapy Human immunodeficiency virus Human papillomaviruse OUTCOME
下载PDF
Ribosome Inactivating Proteins from Plants Inhibiting Viruses 被引量:7
17
作者 Inderdeep Kaur R C Gupta Munish Puri 《Virologica Sinica》 SCIE CAS CSCD 2011年第6期357-365,共9页
Many plants contain ribosome inactivating proteins (RIPs) with N-glycosidase activity, which depurinate large ribosomal RNA and arrest protein synthesis. RIPs so far tested inhibit replication of mRNA as well as DNA v... Many plants contain ribosome inactivating proteins (RIPs) with N-glycosidase activity, which depurinate large ribosomal RNA and arrest protein synthesis. RIPs so far tested inhibit replication of mRNA as well as DNA viruses and these proteins, isolated from plants, are found to be effective against a broad range of viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and herpes simplex virus (HSV). Most of the research work related to RIPs has been focused on antiviral activity against HIV; however, the exact mechanism of antiviral activity is still not clear. The mechanism of antiviral activity was thought to follow inactivation of the host cell ribosome, leading to inhibition of viral protein translation and host cell death. Enzymatic activity of RIPs is not limited to depurination of the large rRNA, in addition they can depurinate viral DNA as well as RNA. Recently, Phase I/II clinical trials have demonstrated the potential use of RIPs for treating patients with HIV disease. The aim of this review is to focus on various RIPs from plants associated with anti-HIV activity. 展开更多
关键词 Ribosome inactivating protein Human immunodeficiency virus Hepatitis B virus Herpes simplex virus
下载PDF
Construction and expression of the bicistronic expression vector with RANTES and SDF-1 genes
18
作者 张颖 白雪帆 +4 位作者 李谨革 黄长形 孙永涛 聂青和 王九平 《Journal of Medical Colleges of PLA(China)》 CAS 2003年第6期369-372,共4页
Objective: To construct bicistronic expression vector with RANTES and SDF-1 genes, the ligands of HIV-1 principal coreceptors, and identify its expression. Methods: RANTES-KDEL was amplified from plasmid pCMV-R-K by P... Objective: To construct bicistronic expression vector with RANTES and SDF-1 genes, the ligands of HIV-1 principal coreceptors, and identify its expression. Methods: RANTES-KDEL was amplified from plasmid pCMV-R-K by PCR and cloned into eukaryotic expression vector pCMV-S/K. Gene transfection into HeLa cells was carried out by lipofectin. Indirect immumofluorescence and radioimmunoprecipitation were used to confirm the expression of RANTES and SDF-1. Results: The construction of pCMV-R-K-S-K was confirmed by enzymatic digestion and sequencing. RANTES and SDF-1 were shown expressed in HeLa cells by indirect immumofluorescence and radioimmunoprecipitation. Conclusion: pCMV-R-K-S-K was constructed and expressed in cell line Hela successfully, which will contribute to further study of gene therapy of AIDS by HIV-1 coreceptors knockout. 展开更多
关键词 HIV-1 CORECEPTOR CHEMOKINE bicistronic expression vector TRANSFECTION indirect immumofluorescence radioimmunoprecipitation
下载PDF
Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis 被引量:11
19
作者 Li-Ping Deng Xi-En Gui Yong-Xi Zhang Shi-Cheng Gao Rong-Rong Yang 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第8期996-1003,共8页
AIM: To analyze the influence of human immunodeficiency virus (HIV) infection on the course of hepatitis C virus (HCV) infection. METHODS: We performed a meta-analysis to quantify the effect of HIV co-infection on pro... AIM: To analyze the influence of human immunodeficiency virus (HIV) infection on the course of hepatitis C virus (HCV) infection. METHODS: We performed a meta-analysis to quantify the effect of HIV co-infection on progressive liver disease in patients with HCV infection. Published studies in the English or Chinese-language medical literature involving cohorts of HIV-negative and -positive patients coinfected with HCV were obtained by searching the PUBMED, EMBASE and CBM. Data were extracted independently from relevant studies by 2 investigators and used in a fixed-effect meta analysis to determine the difference in the course of HCV infection in the 2 groups. RESULTS: Twenty-nine trails involving 16 750 patients were identified including the outcome of histological fibrosis or cirrhosis or de-compensated liver disease or hepatocellular carcinoma or death. These studies yielded a combined adjusted odds ratio (OR) of 3.40 [95% confidence interval (CI) = 2.45 and 4.73]. Of note, studies that examined histological fibrosis/ cirrhosis, decompensated liver disease, hepatocellular carcinoma or death had a pooled OR of 1.47 (95% CI = 1.27 and 1.70), 5.45 (95% CI = 2.54 and 11.71), 0.76 (95% CI = 0.50 and 1.14), and 3.60 (95% CI = 3.12 and 4.15), respectively. CONCLUSION: Without highly active antiretroviral therapies (HAART), HIV accelerates HCV diseaseprogression, including death, histological fibrosis/ cirrhosis and decompensated liver disease. However, the rate of hepatocellular carcinoma is similar in persons who had HCV infection and were positive for HIV or negative for HIV. 展开更多
关键词 Human immunodeficiency virus Hepatitis C virus COINFECTION Disease progression META-ANALYSIS
下载PDF
HIV Vaccine-Challenges and Opportunities
20
作者 Xin MA Cai-jun SUN Feng LI Ling CHEN 《Virologica Sinica》 SCIE CAS CSCD 2007年第6期486-492,共7页
The need for an efficacious HIV/AIDS vaccine remains the highest priority of the world HIV/AIDS agenda. The generation of an efficacious HIV/AIDS vaccine proves an enormous scientific challenge. This article reviews t... The need for an efficacious HIV/AIDS vaccine remains the highest priority of the world HIV/AIDS agenda. The generation of an efficacious HIV/AIDS vaccine proves an enormous scientific challenge. This article reviews the neutralizing antibody problem,elusive immune protection,im-munogen design,pre-existing anti-vector immunity and design of phase 3 vaccine trials and the challenges and opportunities in development of HIV/AIDS vaccine are discussed. 展开更多
关键词 Neutralizing antibody Cellular immune Protective immunity IMMUNOGEN Efficacy studies
下载PDF
上一页 1 2 下一页 到第
使用帮助 返回顶部